Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives Average Recommendation of “Hold” from Brokerages

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have earned a consensus rating of “Hold” from the eleven analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $10.28.

Several equities analysts have issued reports on the company. The Goldman Sachs Group lowered Maravai LifeSciences from a “neutral” rating to a “sell” rating and dropped their price objective for the stock from $7.00 to $4.25 in a report on Thursday, December 5th. William Blair reaffirmed a “market perform” rating on shares of Maravai LifeSciences in a research report on Friday, November 8th. Royal Bank of Canada decreased their price objective on Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a report on Friday, November 8th. Guggenheim started coverage on shares of Maravai LifeSciences in a report on Thursday, December 19th. They issued a “neutral” rating on the stock. Finally, Robert W. Baird reduced their price target on shares of Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating for the company in a research report on Friday, November 8th.

Maravai LifeSciences Trading Down 4.5 %

Shares of Maravai LifeSciences stock opened at $5.13 on Tuesday. The company has a fifty day simple moving average of $6.30 and a 200-day simple moving average of $7.62. Maravai LifeSciences has a 12-month low of $4.28 and a 12-month high of $11.56. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of -3.13 and a beta of -0.08.

Insider Buying and Selling

In other Maravai LifeSciences news, insider Carl Hull acquired 175,000 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were purchased at an average price of $5.64 per share, with a total value of $987,000.00. Following the completion of the acquisition, the insider now directly owns 175,000 shares of the company’s stock, valued at approximately $987,000. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 0.63% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Maravai LifeSciences

Several institutional investors have recently made changes to their positions in the stock. Franklin Resources Inc. purchased a new position in shares of Maravai LifeSciences in the 3rd quarter valued at about $600,000. Barclays PLC lifted its position in shares of Maravai LifeSciences by 349.2% during the 3rd quarter. Barclays PLC now owns 184,189 shares of the company’s stock valued at $1,531,000 after acquiring an additional 143,184 shares during the period. Neo Ivy Capital Management purchased a new stake in shares of Maravai LifeSciences during the 3rd quarter worth approximately $136,000. Geode Capital Management LLC grew its holdings in shares of Maravai LifeSciences by 6.3% in the 3rd quarter. Geode Capital Management LLC now owns 2,752,077 shares of the company’s stock worth $22,874,000 after acquiring an additional 162,601 shares during the period. Finally, Y Intercept Hong Kong Ltd purchased a new position in Maravai LifeSciences in the 3rd quarter valued at approximately $105,000. 50.25% of the stock is currently owned by hedge funds and other institutional investors.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.